Next Generation Pharmaceutical Impactor (NGI)

Next Generation Pharmaceutical Impactor (NGI) Overview

MSP developed this impactor in conjunction with a 15-member consortium of pharmaceutical companies (Next Generation Impactor Consortium).

APPLICATIONS

• Development of metered-dose or dry-powder inhalers
• QA/QC testing of commercial inhaler products

ACCESSORIES

• Automated Rinsers
• USP Inlet
• Pre-Separator
• Vacuum Pump
• Flow Meter
• Timed Flow Controller
• Filter Holder
• Leak Tester

Next Generation Pharmaceutical Impactor (NGI) Specifications

Flow Rate	30 L/min to 100 L/min air flow Particle size fractionation range 0.23µm to 11 µm
Weight	9 Kg

Next Generation Pharmaceutical Impactor (NGI) Design

Substantial user-involvement in the design process has resulted in a combination of aerodynamic design principles and user-friendly operation. A removable set of collection cups minimizes the time between inhaler tests. Other time-saving features include the absence of a final filter and of inlet O-rings. The NGI has been tested by 15 pharmaceutical companies in the NGI Consortium.

Next Generation Pharmaceutical Impactor (NGI) Features

• Designed for productivity
• Hinged lid that is easy to open
• Easy to recover samples from cups
• Easy to prepare for next test
• Removable set of collection cups
• Micro-orifice collector in place of final filter
• O-ring free inlet
• Electrically conductive and corrosion-resistant
• Functions over wide flow range (30 L/min to 100 L/min)
• Incorporates state-of-the-art aerodynamic principles
• Meets USP System Suitability standards
• Sizes particles between 0.23 µm and 11 µm depending on the flowrate
• Seven stages: at lease five with D50 values between 0.5 µm and 6.5 µm at all flow rates
• Calibrated with particles at 60 L/min flow rate
• Low internal particles losses; minimal washing between tests